Research summary ·
Systematic review and network meta-analysis of performance of the Sapporo criteria, the revised Sapporo criteria, and the 2023 ACR/EULAR APS classification criteria for patients with antiphospholipid syndrome.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This review looked at rules used to class people as having APS. APS means antiphospholipid syndrome. It compared the Sapporo rules from 1999 and revised rules from 2006. It also looked at the ACR/EULAR rules from 2023. The team searched for studies up to October 13, 2025. They pooled 7 studies with 8 groups of people. In all, 3,908 people took part, and 2,214 had APS.
What they found
The 2006 rules were the most likely to pick up people with APS. They also had the top score for overall test quality. The 2023 rules missed more people with APS than the 2006 rules. But the 2023 rules rarely labeled people without APS as having it. They also scored highest on a measure of telling the groups apart. The 1999 rules did less well overall.
What it means for patients
The authors say the 1999 rules are of limited use in clinics. They say the 2006 rules are strong at finding people with APS. They say the 2023 rules are better at not wrongly labeling people. In their view, this makes the 2023 rules fit research studies well. The authors add they can help doctors as an extra tool. This is for people whose APS signs are not typical.
Why it is not certain yet
This review pooled only 7 studies. The abstract does not say how much the studies differed. It also does not say whether some results went unpublished. A review can only be as good as the studies in it.
Source
Systematic review and network meta-analysis of performance of the Sapporo criteria, the revised Sapporo criteria, and the 2023 ACR/EULAR APS classification criteria for patients with antiphospholipid syndrome.
PubMed · PMID 42199439We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Antiphospholipid syndrome publications